Full Name
Anne McGeorge CPA
Job Title
Board Member
Company
Dianthus Therapeutics, Starling Oncology, CitiusTech, Numbus Therapeutics, National Marrow Donor Program
Speaker Bio
Anne McGeorge is the former managing partner of Grant Thornton, LLP’s Global Health Care and Life Sciences Practices. She helped launch this focus within the organization and grew it to a $250 million global business in 10 years.
Prior to joining Grant Thornton, LLP, Anne was Partner in charge of Southeast Health Care Tax Practice at Deloitte from 2002 to 2005, and Arthur Andersen from 1994 to 2002. Anne’s 35-year career spans all aspects of finance and transformational change, including strategy, M&A, joint ventures, financial statement audits, corporate restructuring, governance, talent acquisition, executive compensation, IRS matters, and risk management.
Anne is currently on the board of directors for two public companies: Dianthus Therapeutics (NASDAQ: DNTH) and Starling Oncology (NASDAQ: STLN); two private (PE-backed) companies: CitiusTech and Nimbus Therapeutics; and two non-profit companies: The National Marrow Donor Program and the Business School Foundation at William & Mary. She is the chair of the Starling Oncology board and the Audit Committee Chair of the other corporate boards. She is also an Operating Partner for Havencrest Capital Management, a middle market healthcare private equity fund.
She is also on the advisory board for FCA Health Innovations, a $250 million venture capital fund. Anne is a member of WBL, Women on Boards 50/50, and Women Corporate Directors. She is on the adjunct faculty at the Gillings School of Public Health at the University of North Carolina - Chapel Hill. Anne has a B.B.A. in Accounting from William & Mary and an M.S. In Accounting/Taxation from the University of Virginia.
Boards: Dianthus Therapeutics, Starling Oncology, CitiusTech, Numbus Therapeutics, National Marrow Donor Program, Business School Foundation at William & Mary
Prior to joining Grant Thornton, LLP, Anne was Partner in charge of Southeast Health Care Tax Practice at Deloitte from 2002 to 2005, and Arthur Andersen from 1994 to 2002. Anne’s 35-year career spans all aspects of finance and transformational change, including strategy, M&A, joint ventures, financial statement audits, corporate restructuring, governance, talent acquisition, executive compensation, IRS matters, and risk management.
Anne is currently on the board of directors for two public companies: Dianthus Therapeutics (NASDAQ: DNTH) and Starling Oncology (NASDAQ: STLN); two private (PE-backed) companies: CitiusTech and Nimbus Therapeutics; and two non-profit companies: The National Marrow Donor Program and the Business School Foundation at William & Mary. She is the chair of the Starling Oncology board and the Audit Committee Chair of the other corporate boards. She is also an Operating Partner for Havencrest Capital Management, a middle market healthcare private equity fund.
She is also on the advisory board for FCA Health Innovations, a $250 million venture capital fund. Anne is a member of WBL, Women on Boards 50/50, and Women Corporate Directors. She is on the adjunct faculty at the Gillings School of Public Health at the University of North Carolina - Chapel Hill. Anne has a B.B.A. in Accounting from William & Mary and an M.S. In Accounting/Taxation from the University of Virginia.
Boards: Dianthus Therapeutics, Starling Oncology, CitiusTech, Numbus Therapeutics, National Marrow Donor Program, Business School Foundation at William & Mary
Speaking At
